POSSIBLE BREAST CANCER DRUG IN DEVELOPMENT WITH LESS ADVERSE SIDE EFFECTS

 

 BREAST CANCER DRUG IN DEVELOPMENT WITH LESS ADVERSE SIDE EFFECTS

---

Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone therapy, but late effects of these treatments include osteoporosis, sexual dysfunction, and blood clots. Researchers reporting in ACS Central Science have created a novel treatment that eliminated small breast tumors and significantly shrank large tumors in mice in a single dose without problematic side effects.

Most breast cancers are estrogen receptor-positive (ER+), and treatment typically involves several years of hormone therapy. Although these drugs are better tolerated than chemotherapy, they still have side effects that diminish quality of life and can leave people at risk for cancer recurrence and treatment resistance. Thus, there is a need for cancer drugs that kill tumor cells selectively and aggressively while limiting side effects.

To address this challenge, Paul Hergenrother and colleagues previously developed a small molecule called ErSO. This compound kills ER+ breast cancer cells but results in undesirable side effects. In 2022, the researchers synthesized a series of small molecules similar to ErSO. Previous studies demonstrated that these derivatives have higher potency, excellent selectivity for ER+ cancer cells, and better pharmacological properties than the original compound.

Now, in the latest study, the researchers further evaluated one derivative, ErSO-TFPy, and found that it:

• Effectively killed multiple human ER+ breast cancer cell lines in culture.
• It was well tolerated by various species (mice, rats, and beagles with no apparent deleterious effects).
• Shrank transplanted human breast tumors of various genetic backgrounds in mice.

In a dosing experiment, the researchers noted that a single dose of ErSO-TFPy in mice induced complete or near-complete regression of small or large tumors, respectively, that had grown in the animals. Other drugs require long-term dosing, but a lone dose of ErSO-TFPy and minimal circulation in the body could help reduce the risk of side effects and late effects. They acknowledge the need for more testing to confirm drug safety and efficacy. Still, they suggest if these results translate to human patients, ErSO-TFPy could be transformative for ER+ breast cancer treatment.

"It is very rare for a compound to shrink tumors in mouse models of breast cancer, let alone completely eradicate those tumors with a single dose, so we are eager for ErSO-TFPy to advance for treatment of breast cancer," says Hergenrother.

The authors acknowledge funding from the National Cancer Institute at the National Institutes of Health and the Cancer Center in Illinois.

• 
  
  • 
    
  
  
  

• 
  
  • 
    
  •